For how we live.
An FDA advisory committee will meet on 30 October to review Sydnexis's atropine sulfate 0.01% eye drops, proposed to slow myopia progression in children aged 3 and older. The public docket closes 29 October.
In the company-run CONDOR trial, brolucizumab injections outperformed panretinal laser for proliferative diabetic retinopathy over 54 weeks — while intraocular inflammation was far more common in the drug arm.
In the phase 3 TenCRAOS trial, intravenous tenecteplase given within 4.5 hours did no better than aspirin at recovering sight, and carried more bleeding — including one fatal brain haemorrhage.
Open-angle glaucoma steals side vision so slowly that half of people who have it don't know. There is no way to prevent it — but a placebo-controlled trial showed pressure-lowering drops preserve vision.
Floaters are usually ageing changes in the eye's gel. But among people who suddenly develop floaters and flashes, about 14% turn out to have a retinal tear — which can lead to permanent vision loss if left.
Eye exercises won't sharpen blurry sight or cure nearsightedness — glasses and surgery do that. But one focusing problem, convergence insufficiency, does respond: an office-based programme helped 73% in a trial.
By age 80 most people have a cataract or have had one removed. You can lower some risks, but the antioxidant vitamins tested in a 4,629-person trial did not slow them, and surgery is the only cure.
The Essilor-designed HAL lenses cut two-year myopia progression by 71% versus ordinary glasses in 159 American children. The company employs the study's authors, and the result backs the device's US clearance.
Omega-3 supplements are widely recommended for dry eye, but the largest randomised trial found them no better than an olive-oil placebo. A Cochrane review leaves the case uncertain at best.
In the phase 3 THRIVE trial, veligrotug shrank bulging eyes in 70% of patients versus 5% on placebo. It is the first serious challenger to the only drug approved for the condition.
Systems that give a diagnosis with no clinician in the loop post high sensitivity in trials. In real-world use, one in six images was too poor to grade — and the strongest numbers come from company-run studies.
Satralizumab reduced eye-bulging and inflammation in thyroid eye disease across the twin SatraGO phase 3 trials, but the primary proptosis endpoint reached statistical significance in only one of them.
Stargardt disease, the most common inherited macular dystrophy, has no approved treatment. In the 50-patient TEASE-1 trial, gildeuretinol slowed atrophic lesion growth by a fraction of a millimetre a year.
In South Kivu, ophthalmologists examined 310 patients with confirmed clade Ib mpox at four time points. Periorbital lesions and severe acute malnutrition tripled the risk of ocular involvement.
Three of the four Yamanaka factors, delivered to one eye and switched on with an antibiotic for eight weeks. The mouse data are striking; the trial is a safety study and will not measure ageing.
The trials that made eye vitamins a standard recommendation enrolled only people who already had substantial disease. In AREDS2, neither omega-3 nor lutein beat placebo on the primary endpoint.
Two 2026 meta-analyses pooled deep-learning systems reading retinal images for AMD. The accuracy looks near-perfect, but almost all of it comes from algorithms tested on their own data.
EyeFM was tested as an assistant to 16 ophthalmologists screening 668 high-risk patients in China. Patients in the AI arm also followed referral advice more often.
Off-the-shelf features from two published models matched retinal scans to the right patient 78% to 86% of the time. Fine-tuned for the task, one model reached 99.5% on OCT.